LEXINGTON, Mass., Jan. 31 IndevusPharmaceuticals, Inc. (Nasdaq: IDEV) will announce its first quarter fiscal2008 financial results in a press release to be issued before market open onThursday, February 7, 2008. The Company will host a conference call andwebcast to discuss these results at 9:00 AM eastern time on Thursday, February7, 2008.
The live call may be accessed by dialing 888-680-0893 from the U.S. andCanada, and 617-213-4859 from international locations. The participantpasscode is 93441269. Investors are advised to dial into the call at leastten minutes prior to the call to register. Participants may pre-register forthe call athttps://www.theconferencingservice.com/prereg/key.process?key=PWJFVJ69C. Pre-registrants will be issued a pin number to use when dialing into the live callwhich will provide quick access to the conference by bypassing the operatorupon connection. A replay of the call will be available beginning at 11:00 AMon February 7, 2008 and lasting until 12:00 AM on March 7, 2008. To accessthe replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 15551448.
The press release and the live webcast will be accessible by visiting theInvestors section of the Company's website, http://www.indevus.com. Anarchived version of the call will be accessible at the same web address for 30days following the live call.
Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical companyengaged in the acquisition, development and commercialization of products totreat conditions in urology and endocrinology. The Company's approvedproducts include SANCTURA XR(TM) and SANCTURA(R) for overactive bladder,VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precociouspuberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevusdevelopment pipeline contains multiple compounds within the Company's coretherapeutic areas in addition to several partnered or partnerable programs.The most advanced compounds in development include, VALSTAR(TM) for bladdercancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention ofinfection by HIV and other sexually-transmitted pathogens, octreotide foracromegaly, and pagoclone for stuttering.
Forward Looking Statements
Except for the descriptions of historical facts contained herein, thispress release contains forward-looking statements that involve risks anduncertainties that could cause the Company's actual results and financialcondition to differ materially from those anticipated by the forward-lookingstatements. These risks and uncertainties are set forth in the Company'sfilings under the Securities Act of 1933 and the Securities Exchange Act of1934 under "Risk Factors" and elsewhere, and include, but are not limited to:dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS andSUPPRELIN LA; effectiveness of our sales force; competition and its effect onpricing, spending, third-party relationships and revenues; dependence on thirdparties for supplies, particularly for histrelin, manufacturing, marketing,and clinical trials; risks associated with being a manufacturer of some of ourproducts; risks associated with contractual agreements, particularly for themanufacture and co-promotion of SANCTURA and SANCTURA XR and the manufactureof NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual propertyand having limited patents and proprietary rights; dependence on marketexclusivity, changes in reimbursement policies and/or rates for SANCTURA,SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products;acceptance by the healthcare community of our approved products and productcandidates; uncertainties relating to clinical trials, regulatory approval andcommercialization of our products, particularly SANCTURA XR, NEBIDO, andVALSTAR; product liab